"Our main mission is the execution of a >€200 million investment into CapEx projects that will bring additional capacity and technologies online to support pharma and biotech customers as their drug development projects progress."
"To ensure that New Jersey maintains this leadership position, BioNJ will continue to work with State government to support industry and stave off onerous proposals. "
"Our partners benefit from our market intelligence and cost-splitting, and we attain the manufacturing capability and resources. We will continue to grow our partnership model now that we are expecting to double our revenue."
"What we are doing here is beginning the build-out of a high-potency API suite, so that we can get up to a few hundred grams made for early studies and transfer those processes to our sites in Italy for the clinical trial phase."
"Overall, I believe the virtual biotech model is here to stay and companies will increasingly look at CRO/CDMO companies for assistance in taking drugs from discovery to commercialization."
CHAIRMAN AND CEO, XONTOGENY, AND PORTFOLIO MANAGER, PERCEPTIVE XONTOGENY VENTURE (PXV) FUND
"Following a long period of significant investment in early-stage firms, our industry needs to allow existing investments across the industry to mature and show signs of success before driving new investments in preclinical-stage projects."
The pre-release edition of Africa Energy 2024 comprises analysis based on over 80 interviews with ministers and leading executives from IOCs, NOCs, independents, associations, investors and service providers, to provide an in-depth and holistic view of sub-Saharan Africa’s ever-evolving energy sector.